PROGRAM: MONDAY, MAY 22, 2006

8:00AM-8:15AM

WELCOME & INTRODUCTION - Salon E&F

Joanna Siegel ScD, Director, Research Initiative in Clinical Economics, Agency for Healthcare Research & Quality & ISPOR Program Committee Chair, Rockville, MD, USA

8:15AM-8:30AM

PRESIDENTIAL ADDRESS - Salon E&F

Peter Neumann ScD, Center for the Evaluation of Value and Risk in Health, Tufts University School of Medicine, Boston, MA, USA

8:30AM-9:45AM

FIRST PLENARY SESSION

BALANCING AFFORDABILITY AND VALUE: THE UNIVERSAL CHALLENGE IN HEALTH CARE DELIVERY - Salon E&F

Moderator: J. Sanford Schwartz MD , Professor of Medicine, Health Care Management, and Economics, University of Pennsylvania, Philadelphia, PA, USA

Speaker: Leonard Schaeffer, Founding Chairman & CEO, WellPoint Inc., Thousand Oaks, CA, USA

Leonard Schaeffer will discuss health insurers' challenge to balance affordable health care benefits with consumer demand for access to the latest therapies and technology. Schaeffer will explore how leading health plans will increasingly use their data to better understand patient outcomes. He will argue that communicating information back to patients and providers, coupled with incentives, are the key strategies for promoting the shift to evidence-based medicine.

Respondent: Marc Berger MD, Vice President, Outcomes Research & Management, Merck & Company, Inc. West Point , PA, USA

Marc Berger will respond to Leonard Schaeffer's address from two perspectives. First, he will address some of the methodologic challenges to implementation of an evidence-based medicine approach to health technology assessment. Second, he will discuss the additional challenge entailed in balancing cost containment approaches with the desire to maintain appropriate incentives for innovation.

9:45AM-10:15AM

BREAK, EXHIBITS & CONTRIBUTED POSTER PRESENTATIONS VIEWING - SESSION I
Franklin Hall, Level 4

Coffee sponsored by: RTI Health Solutions
Cookies sponsored by: Forest Laboratories

10:15AM-11:15AM

PODIUM SESSION I

Adherence & Compliance - Salon A

AC1
USING TABLET PCS FOR SMOKING HAZARDS EDUCATION IN A METHADONE CLINIC
Finkelstein J, Brown S, Sharma K, Lapshin O
University of Maryland, Baltimore, MD, USA

AC2
THE PREVALENCE OF SUBJECTIVELY EXPERIENCED ADVERSE DRUG REACTIONS. A NATIONWIDE SURVEY IN SWEDEN
Isacson D, Johansson L, Bingefors K
Uppsala University, Uppsala, Sweden

AC3
DETERMINANTS OF NON-COMPLIANCE WITH BISPHOSPHONATE THERAPY IN WOMEN WITH POST-MENOPAUSAL OSTEOPOROSIS
Penning-van Beest FJ1, Van den Boogaard CH1, Erkens JA1, Engbersen AM2, Herings RM3
1PHARMO Institute, Utrecht, Utrecht, Netherlands, 2Novartis Pharma AG, Basel, Switzerland, 3PHARMO Institute, Utrecht, Netherlands

AC4
OCCURRENCE OF THROMBOCYTOPENIA AFTER ORTHOPEDIC SURGERIES IN PATIENTS TREATED WITH FONDAPARINUX, DALTEPARIN, ENOXAPARIN OR UNFRACTIONATED HEPARIN
Sarnes M1, Patel NM2, Happe L3, Farrelly E3
1Applied Health Outcomes, Havertown, PA, USA, 2GSK, Collegeville, PA, USA, 3Applied Health Outcomes, Palm Harbor, FL, USA

Cost Studies - Salon B

CS1
THE ECONOMIC AND HEALTH CONSEQUENCES IN SWEDEN OF MANAGING BRADYCARDIA WITH ADAPTA® COMPARED TO A STANDARD DUAL CHAMBER PACEMAKER
Deniz HB1, Farzana M2, Ward A1, Nicklasson L3, Xenakis J1, O'Brien JA1, Caro JJ1
1Caro Research Institute, Concord, MA, USA, 2Medtronic Europe Sarl, Tolochenaz, Switzerland, 3Medtronic AB, Sweden, Järfälla, Sweden

CS2
ECONOMIC BURDEN OF WORK LOSS AMONG SUFFERERS OF LYMPHATIC FILARIASIS: AN ERADICABLE GLOBAL HEALTH PROBLEM
Singh M1, Pizzi LT1, Lofland JH1, Higashi MK2, Patel NM3
1Thomas Jefferson University, Philadelphia, PA, USA, 2Glaxo Smith Kline Pharmaceuticals, Philadelphia, PA, USA, 3GSK, Collegeville, PA, USA

CS3
THE EFFECT OF ORGAN THREATENING AND MENTAL HEALTH CO-MORBIDITIES ON MEDICAL COSTS IN SYSTEMIC LUPUS ERYTHEMATOSUS
Zhang L, Nichol MB
University of Southern California, Los Angeles, CA, USA

CS4
FREQUENCY AND COST OF DISABILITY AMONG EMPLOYED INDIVIDUALS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Darkow T1, Kadlubek PJ1, Shah H2, Phillips AL2, Martön JP3
1i3 Magnifi, An Ingenix Company, Eden Prairie, MN, USA, 2Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA, 3Pfizer Pharmaceuticals Group, Pfizer Inc, New York, NY, USA

Health Care Use & Policy - Salon C

HP1
RECENT POLICY INITIATIVES IN THE AUSTRALIAN NATIONAL REIMBURSEMENT SYSTEM THAT HAVE REDUCED COST DRAMATICALLY
Abela M, Davey P, Scott E, Carroll J
M-TAG Pty Ltd, Chatswood, NSW, Australia

HP2
THE IMPACT OF BARIATRIC SURGERY ON HEALTH OUTCOMES AND PHARMACOLOGICAL TREATMENT AMONG OBESE PATIENTS IN AN EMPLOYED POPULATION
Crémieux PY1, Ledoux S2, Clerici C2, Moyneur É1, Salomon L2, Crémieux F2
1Analysis Group, Inc, Boston, MA, USA, 2Hôpital Louis Mourier, Colombes, France

HP3
DETERMINANTS OF GENERIC ENTRY IN LAST DECADE
Rhee J
UCLA, Los Angeles, CA, USA

HP4
PRESCRIPTION DRUG INSURANCE AND ITS EFFECT ON UTILIZATION AND HEALTH OF THE ELDERLY
Khan N
University of Illinois at Chicago, Chicago, IL, USA

Patient-Reported Outcomes I - Salon D

PR1
A BAYESIAN ESTIMATION OF AN AVERAGE SF-6D PREFERENCE BASED SCORE FROM COMMONLY REPORTED SF-12 STATISTICS
Hanmer J, Fryback DG
University of Wisconsin - Madison, Madison, WI, USA

PR2
QUANTIFYING PATIENTS' RISK-BENEFIT TRADEOFF PREFERENCES: A CONCEPTUAL AND EMPIRICAL COMPARISON OF METHODS
Johnson FR1, Van Houtven G1, Mansfield C1, Ozdemir S1, Miller DW2
1Research Triangle Institute, Research Triangle Park, NC, USA, 2Elan Pharmaceuticals, San Diego, CA, USA

PR3
RACIAL DIFFERENCES IN PREFERENCE-BASED HEALTH-RELATED QUALITY OF LIFE ASSESSMENT
Fu AZ, Kattan MW
Cleveland Clinic Foundation, Cleveland, OH, USA

PR4
CONVERTING THE SCORES OF A CLINICAL INSTRUMENT FOR MEASURING PAIN TO A PREFERENCE BASED ONE
Iskedjian M1, Bereza B1, Desjardins O1, Jaszewski B2, Piwko C1, Einarson TR3
1PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, 2Bayer Healthcare, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada

Respiratory Disorders - Salon E & F

RS1
TRENDS IN MEDICATION PRESCRIBING FOR CHILDREN WITH SLEEP DISORDERS IN US OUTPATIENT SETTINGS
Rasu RS1, Balkrishnan R2, Nahata MC2
1University of Missouri Kansas City, Kansas City, MO, USA, 2The Ohio State University College of Pharmacy, Columbus, OH, USA

RS2
COST-EFFECTIVENESS OF TELITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
McGarry LJ1, Iskandar R2, Seal B3, Asche C4, Thompson D5, Weinstein MC6
1i3 Innovus, Medford, MA, USA, 2i3 Innovus, Medford, MA, USA, 3Sanofi-Aventis, Bridgewater, NJ, USA, 4The University of Utah College of Pharmacy, Salt Lake City, UT, USA, 5i3 Innovus Medford, MA, USA, 6i3 Innovus, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA

RS3
LONG TERM SURVIVAL AS A FUNCTION OF AIRWAY OBSTRUCTION (FEV1) IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A POPULATION BASED RECORD LINKAGE STUDY IN A LARGE UK POPULATION
Woehl A1, Morgan CL2, Currie CJ3
1Cardiff University, Cardiff, United Kingdom, 2Cardiff University, Cardiff, Wales, United Kingdom, 3Department of Medicine, Cardiff, Wales, United Kingdom

RS4
AN EVALUATION OF THE ASSOCIATION BETWEEN HEALTH CARE UTILIZATION AND USE OF SALMETEROL AMONG SUBJECTS WITH ASTHMA
Wang MT, Malone DC, Skrepnek GH
University of Arizona, Tucson, AZ, USA

11:30AM-12:30PM

ISSUE PANEL - SESSION I (4 ISSUE PANELS)

IP1: WILL THE QALY SURVIVE? - Salon E & F
(Invited Issue Panel)

Moderator: Michael Drummond PhD, Professor of Health Economics, University of York, Centre for Health Economics, Heslington, York, UK

Panelists: Daniel Kahneman PhD , Psychology; Professor of Psychology and Public Affairs Woodrow Wilson School, Princeton University, Princeton, 2002 Bank of Sweden Prize in Economic Sciences in Memory of Alfred Nobel, Princeton, NJ, USA; Dennis Fryback PhD Professor of Population Health Sciences and Industrial Engineering , Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA; Alistair McGuire PhD, Professor in Health Economics, London School of Economics, London, UK

HEALTH CARE REIMBURSEMENT/COVERAGE

IP2: THE NEW NATIONAL INSTITUTE OF HEALTH AND CLINICAL EXCELLENCE (NICE) SINGLE TECHNOLOGY APPRAISAL (STA) PROCESS: EXPERIENCE FROM THE FIRST ROUND OF SUBMISSIONS - Salon A

Moderator: Shahnaz Khan MPH, Senior Health Outcomes Communications Specialist, RTI Health Solutions, RTP, NC, USA
Panelists: Sorrel Wolowacz PhD, Senior Health Economist, RTI Health Solutions, United Kingdom;
Mark Sculpher PhD, MSc, Professor, Centre for Health Economics, University of York, UK

USE OF HEALTH ECONOMIC/ PHARMACOECONOMIC INFORMATION BY DECISION-MAKERS

IP3: PAYOR ORIENTED EVIDENCE GUIDELINES - Salon B

Moderator: Joseph Singer MD, Vice President Integrated Research, HealthCore, Inc, Wilmington, DE, USA

Panelists: Brian Sweet, MBA, BS Pharmacy, VP Clinical Services, WellPoint Pharmacy Management, West Hills, CA, USA; Dennis Raisch PhD, RPh, MS, Associate Center Director, Scientific Affairs, VA Cooperative Studies Program Clinical Research Pharmacy, Albuquerque, NM, USA

IP4: LOST IN SPACE: REIMBURSEMENT FOR PHARMACOGENOMICS - Salon C

Moderator: Louis Rossiter PhD, Senior Research Fellow, The College of William & Mary, Williamsburg, VA, USA
Panelist(s): C. Randal Mills Mills PhD, President and Chief Executive Officer, Osiris Therapeutics, Inc, Baltimore, MD, USA; Kathryn A. Phillips PhD, Professor of Health Economics & Health Services Research, University of California, San Francisco, San Francisco, CA, USA

12:30PM-2:00PM

LUNCH, EXHIBITS & CONTRIBUTED POSTER PRESENTATIONS VIEWING - SESSION I
GRAND OPENING - Franklin Hall Level 4

Lunch Sponsored by Caro Research

1:00PM-2:00PM

HANDLING ISSUES AROUND MISSING DATA IN ECONOMIC ANALYSIS - Salon E&F

An Educational Symposium Sponsored by IMS Health

Presentations and discussion of the relevance of handling missing data for health economic evaluations and examples of how missing data can be addressed. Specific topics like the impact of not correctly addressing missing data, and exploration of different techniques will be covered.

1:00PM – 1:05PM
OPENING REMARKS

Moderator: Lieven Annemans, PhD, MSc, MMan, Principal Health Economics and Outcomes Research, Professor Health Economics University of Gent, Brussels, Belgium

1:05PM – 1:25PM
THE NEED TO ADDRESS MISSING DATA ISSUES IN HEALTH ECONOMIC EVALUATIONS

The correct addressing of missing data in prospectively or retrospectively collected datasets for health economic research purposes can have an important influence on the final outcomes of the analysis and the health economic conclusions. The impact of ignoring this importance is illustrated.

Speaker: John Cook, PhD, Senior Director, Health Economic Statistics, Merck Research Labs, Blue Bell, PA, USA

1:25PM – 1:45PM
POSSIBLE SOLUTIONS FOR HANDLING MISSING DATA IN DATABASES USED FOR HEALTH ECONOMIC EVALUATIONS

Missing data is a common problem in retrospective databases, particularly those with medical or health-economic data. Issues and biases associated with both randomly and systematically missing information will be explored, as will the benefits and drawbacks of techniques used to handle missing data, including simple and multiple imputation, multivariate classification, restriction to evaluable samples, and newer separation inference methods will be described.

Speaker: Dan Ollendorf, MPH, Vice President, Applied Research, PharMetrics, Inc., Watertown, MA, USA

1:45PM – 2:00PM
OPEN DISCUSSION

2:00PM-3:00PM

CONTRIBUTED WORKSHOPS - SESSION I (8 WORKSHOPS, 6 CATEGORIES)

Clinical Study Methodology

W1: COMPARATIVE EFFECTIVENESS RESEARCH FOR DESIGNING THERAPEUTIC SUBSTITUTION POLICIES: HOW SHOULD WE COMBAT UNMEASURED CONFOUNDING?
Salon A
DISCUSSION LEADERS: Sebastian Schneeweiss MD, ScD, Associate Professor or Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; M. Alan Brookhart PhD, Instructor in Medicine (Biostatistics), Harvard Medical School / Brigham and Women's Hospital, Boston, MA, USA; Robert J Glynn PhD, ScD, Associate Professor of Medicien (Biostatistics), Harvard Medical School / Brigham and Women's Hospital, Boston, MA, USA

Compliance/Adherence

W2: METHODS FOR MEDICATION COMPLIANCE STUDIES: PATIENT COMPLIANCE AS A PREDICTOR OF CLINICAL AND ECONOMIC OUTCOMES
Salon B
DISCUSSION LEADERS: Joyce Cramer, Associate Research Scientist, Yale University School of Medicine, West Haven, CT, USA; Femida Gwadry-Sridhar PhD, Assistant Professor, University of Western Ontario, and London Health Sciences Centre, London, ON, Canada; Joshua S. Benner PharmD, ScD, Principal, ValueMedics Research, LLC, Falls Church, VA, USA

Cost Study Methodology

W3: BEWARE OF LOGS: ISSUES TO CONSIDER WHEN ASKING “TO LOG OR NOT TO LOG?”
Salon C
DISCUSSION LEADERS: Jalpa A Doshi PhD, Research Assistant Professor of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Jieling Chen PhD, Health Economist, Merck Research Labs, Blue Bell, PA, USA; Henry A Glick PhD, Assistant Professor of Medicine, University of Pennsylvania, Philadelphia, PA, USA

W4: INCORPORATING COMPLIANCE MEASURES IN RETROSPECTIVE COST STUDIES
Salon D
DISCUSSION LEADERS: Antoine C El Khoury PhD, Post-Doctoral Fellow, University of Maryland, Baltimore, MD, USA; C. Daniel Mullins PhD, Professor and Chair, University of Maryland School of Pharmacy, Baltimore, MD, USA; Fadia T Shaya PhD, MPH, Assistant Professor, Associate Director, University of Maryland, Baltimore, MD, USA

Formulary Development

W5: USING ANONYMOUS PATIENT-LEVEL LONGITUDINAL DATA TO SUPPORT FORMULARY POLICY AND COVERAGE DECISIONS
Salon E & F
DISCUSSION LEADERS: Stephen J. Boccuzzi PhD, MBA, Vice President and Chief Scientific Officer, PharMetrics, a unit of IMS, Watertown, MA, USA; Dan Ollendorf MPH, Vice President, Applied Research, PharMetrics, a unit of IMS, Watertown, MA, USA; Michael E. Minshall MPH, Principal, CORE-USA, a unit of IMS, Fishers, IN, USA

Health Care Policy Development

W6: COLLECTING AND USING MEDICATION DATA FROM NATIONALLY REPRESENTATIVE PROVIDER-BASED SURVEYS
Liberty A
DISCUSSION LEADERS: Lisa L. Dwyer MPH, Health Scientist, National Center for Health Statistics, Hyattsville, MD, USA; Saeid Raofi MS, Pharmacoepidemiologist, National Center for Health Statistics, Hyattsville, MD, USA; Karen A. Lees MPH, Epidemiologist, National Center for Health Statistics, Hyattsville, MD, USA

W7: METHODS FOR QUANTIFYING THE GENEROSITY OF PHARMACY BENEFIT PLANS
Liberty C
DISCUSSION LEADERS: Nicole M. Nitz PhD, Researcher, i3 Innovus, an Ingenix Company, Eden Prairie, MN, USA; Rachel Halpern PhD, Researcher, Health Economics & Outcomes, Eden Prairie, MN, USA

QoL/PRO Methodology Issues

W8: WHAT TYPE OF OUTCOME MEASURE IS THIS?
Room 401
DISCUSSION LEADERS: Judith T Barr ScD, Director, NERCOA, Northeastern University, Boston, MA, USA; Pennifer Erikson PhD, President, OLGA, Pennsylvania State University, State College, PA, USA

2:00PM-4:00PM

STUDENT MOCK INTERVIEW SESSION (Pre-registration required)

3:00PM-3:15PM

BREAK, EXHIBITS & CONTRIBUTED POSTER PRESENTATIONS VIEWING - SESSION I
Franklin Hall Level 4

Coffee sponsored by: RTI Health Solutions
Cookies sponsored by: Forest Laboratories

3:15PM-4:15PM

CONTRIBUTED WORKSHOPS - SESSION II (8 WORKSHOPS, 6 CATEGORIES)

Clinical Study Methodology

W9: ANALYTICAL AND STATISTICAL CONSIDERATIONS IN THE DESIGN, CONDUCT AND ANALYSIS OF PROSPECTIVE PHASE IV STUDIES
Salon A
DISCUSSION LEADERS: Eric K Gemmen MA, Executive Director, Phase IIIb/IV Data Analysis & Health Economics, Quintiles Strategic Research Services, Falls Church, VA, USA; Hany Zayed PhD, Senior Statistical Scientist, Quintiles Strategic Research Services, San Francisco, CA, USA; Murtuza Bharmal BPharm, MS, PhD, Senior Health Outcomes Associate, Quintiles Strategic Research Services, Falls Church, VA, USA

Compliance/Adherence

W10: ADHERENCE: HOW DO WE MEASURE IT, AND WHOSE ADHERENCE ARE WE MEASURING?
Salon B
DISCUSSION LEADERS: Lisa Mucha PhD, Research Leader, Thomson Medstat, Cambridge, MA, USA; Tami Mark MBA, PhD, Associate Director, Thomson, Washington, DC, USA; Kathleen Foley PhD, Research Leader, Thomson Medstat, Philadelphia, PA, USA

Cost Study Methodology

W11: CREATIVE USES OF LINKED SEER-MEDICARE DATA IN MODEL-BASED PHARMACOECONOMIC EVALUATIONS
Salon C
DISCUSSION LEADERS: Kathy Lang PhD, Senior Consultant, i3 INNOVUS, Medford, MA, USA;
Michael E Stokes MPH, Research Analyst, i3 INNOVUS, Medford, MA, USA; Milton C Weinstein PhD, Principal Consultant, i3 INNOVUS, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA

W12: PRESENTING UNCERTAINTY IN COST EFFECTIVENESS RESEARCH
Salon D
DISCUSSION LEADERS: Katia Noyes PhD, MPH, Assistant Professor, University of Rochester School of Medicine, Rochester, NY, USA; Elisabeth Fenwick PhD, Lecture, University of Glasgow, Glasgow, United Kingdom

Formulary Development

W13: FORMULARY DECISIONS FOR MEDICARE PART D
Salon E & F
DISCUSSION LEADERS: Fadia T Shaya PhD, MPH, Assistant Professor, Associate Director, University of Maryland, Baltimore, MD, USA; C. Daniel Mullins PhD, Professor and Chair, University of Maryland School of Pharmacy, Baltimore, MD, USA; Winston Wong PharmD, Director, Pharmacy Management, CareFirst BlueCross BlueShield, Baltimore, MD, USA

Health Care Policy Development

W14: WHAT HEALTH OUTCOMES RESEARCHERS NEED TO KNOW ABOUT MEDICARE PART D
Liberty A
DISCUSSION LEADERS: Diane Simison PhD, Executive Director, Center for Pricing and Reimbursement, United BioSource Corporation, Arlington, VA, USA; Sandy Robinson MPA, Deputy Director, Center for Pricing and Reimbursement, United BioSource Corporation, Arlington, VA, USA; Beth Hahn PhD, Managing Director, Center for Pricing and Reimbursement, United BioSource Corporation, Arlington, VA, USA

W15: EFFECTIVE HEALTH CARE: ASSESSING, DEVELOPING, AND COMMUNICATING EVIDENCE FOR HEALTH CARE DECISIONS
Liberty C
DISCUSSION LEADERS: Jean Slutsky PA, MSPH, Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, MD, USA; Mark Helfand MD, MPH, Director, Oregon Evidence-based Practice Center, Professor of Medicine and Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Portland, OR, USA; Scott R. Smith MSPH, PhD, Pharmaceutical Outcomes Portfolio Lead, Agency for Healthcare Research and Quality, Rockville, MD, USA

Risk Assessment

W16: REDEFINING RISK AND UNCERTAINTY IN OUTCOMES RESEARCH: COMING TO TERMS WITH THE UNKNOWN
Room 401
DISCUSSION LEADERS: John F P Bridges PhD, Health Economist, University of Heidelberg, Heidelberg, Germany; Joshua Graff Zivin PhD, Assistant Professor, Columbia University, New York, NY, USA;
Rachael Molnar MS, MD/PhD Fellow, Case Western Reserve University, Cleveland, OH, USA

4:30PM-5:30PM

ISPOR FORUMS

4:30PM – 5:30PM

WHAT STUDENTS SHOULD KNOW ABOUT MEDICARE PART D - Salon A

Three speakers will discuss Medicare Part D from various perspectives. The effects the Medicare Prescription Drug Benefit is having on a variety of individuals will be presented.

Moderator: Zeba Khan PhD, Executive Director, Pricing, General Medicines, Novartis Pharmaceuticals, East Hanover, NJ, USA; and Joshua Epstein, PhD Student, University of Southern California, Santa Monica, CA, USA

Speakers: Sandra Blake PhD, Director, Outcomes Research, University of Louisiana at Monroe, Monroe, LA USA; Jalpa Doshi PhD, Research Assistant Professor of Medicine, University of Pennsylvania, Philadelphia, PA, USA; and Joyce Addo-Atuah, University of Tennessee, Memphis, TN, USA

4:30PM – 5:30PM	INTERNATIONAL PERSPECTIVES REGARDING PHARMACEUTICAL RISK MANAGEMENT- Salon D
	Moderator: Dennis Raisch, PhD, RPh, BS, MS, Associate Center Director, Scientific Affairs, VA Cooperative Studies Program Clinical Research Pharmacy, Albuquerque, NM, USA Speakers: Suellen Curkendall PhD, Principal Investigator, Cerner Health Insights, Vienna, VA, USA; Larry Liu MD, PhD, Director, Anti-Infectives US Outcomes Research, Pfizer, New York, NY, USA; Anthony Lockett MBA, MD, PhD, ICO, Leeds, W. Yorkshire, UK; Ateequr Rahman MBA, PhD, Assistant Professor, College of Pharmacy, Shenandoah University, Winchester, Virginia, USA Description: Through studying the current environment of risk management (RM) in health care, the RM SIG identified several differences in perceptions of risk management and risk/benefit of pharmaceuticals. We also identified key discrepancies in the regulatory requirements of the Food and Drug Administration and the European Union. We will compare and contrast RM from an international perspective. Then we will provide an open forum for discussion of international issues regarding RM.

4:30PM – 5:30PM	THE ECONOMICS, DETERMINANTS, & METHODS OF ANALYSIS OF MEDICATION COMPLIANCE & PERSISTENCE - Salon B
*4:30*PM-4:35PM	Moderator: Joyce Cramer BS, Medication Compliance & Persistence SIG Chair & Associate Research Scientist, Yale University School of Medicine, West Haven, CT, USA
*4:35*PM-4:45PM	Methods for Analysis of Compliance and Persistence Methods for use of retrospective data to measure compliance, a checklist for the measurement of compliance in prospective studies, and key issues in the statistical distributions of different compliance measures. Approaches to new methods will be described, focusing on concepts that may improve validity and reliability. Speaker: Andrew Peterson PharmD, Analyses Standards WG Leadership Group & Associate Professor, University of the Sciences in Philadelphia, Philadelphia, PA, USA
*4:45*PM-5:00PM	Determinants Of Medication Compliance And Persistence The literature on interventions that have been used to improve compliance has been missing a theoretical framework or hypothesis detailing an expected effect of the intervention on compliance. Examples of frameworks include individual level, interpersonal level and community level factors that may have either a direct effect on compliance or act as a mediator. Models can be developed for researchers developing prospective studies to consider relevant constructs in the development and delivery of interventions to improve compliance. Speaker: Femida Gwadry-Sridhar, PhD, RPh, MSc, BSc Phm, Determinants of Compliance & Persistence Working Group Chair & Associate Director Critical Care Research Network and Assistant Professor, Department of Medicine, University of Western Ontario, ON, Canada
*5:00*PM-5:15PM	Economics of Compliance & Persistence Economic models of behavior can be related to medication-taking behaviors. Models include (a) derivations of Neumann-Morgenstern utility theory to explain decisions under uncertainty about present and future health production and consumption; (b) the quantification by patients of those utilities using stated preference methods; (c) bilateral bargaining models to explore patient provider interactions; (d) prospect theory models to examine how choices vary depending on the reference point (i.e., original health state) when faced with risk or uncertainty; and (e) issues related to time preferences and discount rates. Speaker: Judith Shinogle PhD, MSc, Economics of Compliance and Persistence Leadership Group & Senior Economist, RTI International, Washington, DC, USA
*5:15*PM-5:30PM	Discussion

4:30PM – 5:30PM	REAL WORLD DATA: IMPORTANCE, LIMITATIONS & NEED FOR GOOD RESEARCH PRACTICES - Liberty A
	The ISPOR Task Force on Real-World Data has prepared a draft final report and circulated it for review and comment to a large internal ISPOR Reference Group. This session will review key elements of the draft report, the feedback received from the Reference Group, and issues that need further discussion. The audience will be invited to comment and discuss those issues to assist the Task Force in its final deliberations. Real World Data Task Force, Co-Chairs: Peter Neumann, ScD, Tufts University School of Medicine, Boston, MA, USA & Lou Garrison, PhD, University of Washington, Seattle, WA, USA

4:30PM – 5:30PM	HTA / EBM FOR REIMBURSEMENT DECISIONS SIG FORUM - Salon C
	Health Technology Assessment and Evidence-based Medicine for Reimbursement Decisions SIG, Chairs: Diane Simison PhD, United BioSource Corporation, Alexandria, VA, USA and Frank Papatheofanis MD, MPH, PhD, University of California at San Diego, San Diego, CA, USA This Forum will discuss health technology assessment/Evidence-based Medicine and reimbursement research standards and methods, and how HTA/EBM can help in decision making.

4:30PM – 5:30PM	ISSUES IN ASSESSING GOOD PRACTICE GUIDELINES FOR BUDGET IMPACT ANALYSES - Liberty C
	Moderators: Task Force Co-Chairs: Josephine Mauskopf PhD, VP, Health Economics, RTI Health Solutions, RTI International, Research Triangle Park, NC, USA; Sean Sullivan MS, PhD, RPh, Professor and Director, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA Speakers: Lieven Annemans MSc, PhD, Health Economist Ghent University, Senior Consultant Global Health Economics, HEDM and IMS Health, Brussels, Belgium; J. Jaime Caro MD, Scientific Director, Caro Research, Concord, MA, USA; C. Daniel Mullins PhD, Professor and Chair, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA; Mark Nuijten MBA, MD, PhD, Sr. Research Scientist, Dir. of Business Dev., MEDTAP International, Inc., Jisp, The Netherlands; Ewa Orlewska PhD, Lecturer, Pharmacoeconomics Centre Warsaw, Warsaw, Poland; Paul Trueman MA, Sales & Marketing Director, York Health Economics Consortium, University of York, York, UK; John Watkins MPH, RPh, Pharmacy Manager, Formulary Development, Premera Blue Cross, Bothell, WA, USA; Andrew Wilson BMedSc, MB SC, FRACP, MSc, Deputy Director and Professor of Public Health, University of Queensland, School of Public Health, Brisbane, Australia Description: The mission of this task force is to develop a coherent set of methodological guidelines for those developing or reviewing budget impact analyses. The methodological guidelines will build on previous work both in the published literature and presented in regulatory guidelines. The task force is working closely with regulatory agencies in different countries to ensure that the guidance in the task force report will provide information about the budget impact of a new health care intervention in a format that is useful for decision makers. During the Budget Impact Task Force Forum, task force members will present the key recommendations from the draft task force report about the analytic framework, the inputs and data sources, and reporting format for a budget impact analysis. The task force speakers will describe each key recommendation and its rationale and will invite comment from the forum attendees.
4:30PM – 5:30PM	ISPOR Vision 2010 Implementation Task Force
	During this forum, the ISPOR 2010 task force will share a first version of a new plan establishing proposed actions for ISPOR to meet the Vision 2010 objectives.

5:30PM-6:30PM

ISPOR ANNUAL BUSINESS MEETING - Salon F

Call To Order: Peter Neumann ScD, 2005-2006 ISPOR President
Executive Director’s Report: Marilyn Dix Smith PhD, ISPOR Executive Director
Treasurer’s Report: Lorne Basskin PharmD, ISPOR Treasurer
Audit Report: Joyce Cramer, Chair, ISPOR Audit Committee
Value In Health Editor-In-Chief Report: Josephine Mauskopf PhD, Value in Health Editor-in-Chief
ISPOR CONNECTIONS Editor-In-Chief Report: Steve Marx PharmD, MS, ISPOR CONNECTIONS Editor-in-Chief
Member Open Discussion – ISPOR members
New Business: Peter Neumann ScD, 2005-2006 ISPOR President
Meeting Adjournment: Peter Neumann ScD, 2005-2006

6:00PM-8:00PM

EXHIBITORS' OPEN HOUSE RECEPTION & CONTRIBUTED POSTER PRESENTATION - SESSION I
Franklin Hall , Level 4

Reception sponsored by UBC

8:15PM-11:30PM

ISPOR SOCIAL EVENT: ISPOR ROCKS AT THE HARD ROCK CAFE
Buy tickets online now!
Great networking opportunity! The Hard Rock Café Philadelphia is located directly next door to the Marriott Philadelphia Downtown. Please see registration desk for more details.